
James L Ferrara, MD
About Me
Dr. James Ferrara is a physician-scientist whose clinical and research career has focused on the immunology of bone marrow transplantation (BMT), particularly its major complication graft-versus-host-disease (GVHD). Using trailblazing proteomic techniques, his team has identified and validated unexpected biomarkers for skin, gut and steroid-resistant GVHD. He has created exceptionally large and informative biorepositories and then mined them to meld these biomarkers into the first algorithm that predicts response to treatment and that can guide GVHD therapy. Dr. Ferrara’s pioneering mechanistic studies have illuminated unexpected interactions between the innate and adaptive immune systems and have led to both conceptual breakthroughs and the discovery of novel therapeutic targets. A superb clinician and world-class clinical investigator, his decades-long focus on GVHD has significant potential impact in making BMT safer and more effective for all patients.
Dr. Ferrara graduated Cum laude from Georgetown Medical School and then completed his pediatric residency and fellowship at Boston’s Children’s and the Dana-Farber Cancer Institute. After 19 years at he went to the University of Michigan to direct the combined adult and pediatric BMT program. The Icahn School of Medicine at Mout Sinai recruited Dr. Ferrara in 2014 to become the Ward-Coleman professor of Cancer medicine and to direct the Center for Translational Research in Hematologic Malignancies.
Language
English
Position
PROFESSOR | Medicine, Hematology and Medical Oncology, PROFESSOR | Pediatrics, PROFESSOR | Oncological Sciences, PROFESSOR | Immunology & Immunotherapy
Research Topics
Cytokines, Immunological Tolerance, Immunology, Inflammation, Stem Cells, Transplantation
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Immunology [IMM]
Clinical Focus
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Bone Marrow Transplantation
- Bone Marrow Transplantation, Allogeneic
- Bone Marrow Transplantation, Autologous
- Hematologic Malignancies
- Hematologic Malignancies, Pediatric
- Leukemia
- Leukemias, Pediatric
- Lymphoma
- Myelodysplastic Syndromes
- Myelofibrosis
- Myeloproliferative Disorders
- Transplantation
Video
Publications
Selected Publications
- Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity. Ioannis Evangelos Louloudis, Yi Bin Chen, Nikolaos Spyrou, Amin Alousi, Nikolaos Katsivelos, Francis Ayuk, Daniela Weber, William J. Hogan, Aaron M. Etra, Muna Qayed, Paibel Aguayo-Hiraldo, Yu Akahoshi, Monzr M.Al Malki, Javier Bolaños-Meade, Chantiya Chanswangphuwana, Marcio Diniz, Matthias Eder, Elizabeth Hexner, Carrie L. Kitko, Sabrina Kraus, Pietro Merli, Timothy Olson, Margaret L. MacMillan, Joseph Pidala, Ran Reshef, Tal Schechter, Matthias Wölfl, Janna Baez, Gilbert Eng, Sigrun Gleich, Rachel Young, Ryotaro Nakamura, James L.M. Ferrara, John E. Levine. Transplantation and Cellular Therapy
- The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD. Yu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, Ioannis E. Louloudis, Paibel Aguayo-Hiraldo, Francis Ayuk, Chantiya Chanswangphuwana, Hannah K. Choe, Matthias Eder, Aaron M. Etra, Elizabeth O. Hexner, Carrie L. Kitko, Sabrina Kraus, Pietro Merli, Timothy S. Olson, Ivan Pasic, Muna Qayed, Ran Reshef, Tal Schechter, Julia Marx, Evelyn Ullrich, Ingrid Vasova, Daniela Weber, Matthias Wölfl, Robert Zeiser, Janna Baez, Gilbert Eng, Sigrun Gleich, Steven Kowalyk, George Morales, Nikolaos Spyrou, Rachel Young, Zachariah DeFilipp, William J. Hogan, Ryotaro Nakamura, John E. Levine, James L.M. Ferrara. Blood advances
- Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD. Aaron Etra, James L.M. Ferrara, John E. Levine. Blood